Cetuximab-induced esophageal ulcer: the first report in literature

Taner BabacanDepartment of OncologySchool of Medicine, Hacettepe University, Ankara, Turkey

Ibrahim Halil TurkbeylerDepartment of Internal Medicine School of Medicine, Adiyaman University, Adiyaman, Turkey. Email: [email protected]

Muhammet Sait DagDepartment of Gastroenterology School of Medicine, Gaziantep University, Gaziantep, Turkey

Ismail DilliDepartment of Internal Medicine School of Medicine, Gaziantep University, Gaziantep, Turkey

Ozan BalakanDepartment of Oncology School of Medicine, Gaziantep University, Gaziantep, Turkey

Kadri AltundagDepartment of OncologySchool of Medicine, Hacettepe University, Ankara, Turkey

References

Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, etal. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007; 357: 2040–8.
Google Scholar
Burtness B, Anadkat M, Basti S, Hughes M, Lacouture ME, McClure JS, etal. NCCN Task Force report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Cancer Netw. 2009; 7: 5–21.
PubMed Web of Science ®Google Scholar
Tol J, Cats A, Mol L, Koopman M, Bos MM, van der Hoeven JJ, etal. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs. 2008; 26: 393–7.
Google Scholar
Tarnawski AS. Cellular and molecular mechanisms of gastrointestinal ulcer healing. Dig Dis Sci. 2005; 50: 24–33.
PubMed Web of Science ®Google Scholar
Moehler M, Frings C, Mueller A, Gockel I, Schimanski CC, Biesterfeld S, etal. VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J Gastroenterol. 2008; 14: 4156–67.
Google Scholar